Grupo de Virología Clínica, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidad de A Coruña. A Coruña, Spain.
Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Complejo Hospitalario Universitario de Ferrol (CHUF), SERGAS. Ferrol, Spain.
J Med Virol. 2017 Jul;89(7):1304-1308. doi: 10.1002/jmv.24766. Epub 2017 Mar 14.
The aim of the study was to characterize HCV infection in Northwest Spain and assess the impact of the Spanish Strategic Plan to cure HCV infection. Overall, 387 patients were included (60.9% HIV/HCV coinfected and 28.2% cirrhotic). Of these, 72.9% of patients that were recognized as priority for HCV treatment according to the Spanish Strategic Plan (≥F2, transplant or extrahepatic manifestations), initiated treatment during 2015. Globally, SVR12 was achieved in 96.5% of patients. The implementation of the Spanish Strategic Plan has been critical to advance in HCV cure, but 27.1% of priority patients still remain awaiting HCV treatment initiation.
本研究旨在描述西班牙西北部的 HCV 感染情况，并评估西班牙 HCV 感染治疗策略计划的影响。共纳入 387 例患者（60.9% HIV/HCV 合并感染，28.2%肝硬化）。其中，72.9%的患者根据西班牙 HCV 感染治疗策略计划（≥F2、移植或肝外表现）被确认为 HCV 治疗的优先对象，于 2015 年开始治疗。总体而言，96.5%的患者获得了 SVR12。西班牙 HCV 感染治疗策略计划的实施对于 HCV 治愈的推进至关重要，但仍有 27.1%的优先患者尚未开始 HCV 治疗。
